Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$3.99 USD
+0.31 (8.42%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $3.99 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth C Momentum D VGM
Industry / Sector Report
Industry : Medical - Generic Drugs
Zacks Industry Rank
Bottom 43% (141 out of 248)Zacks Sector Rank
Top 50% (8 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.09 | 1.42 | 9.99 |
Current Quarter Estimate | -0.10 | 1.25 | 57.00 |
Year Ago Quarter Estimate | -0.38 | -4.28 | 52.54 |
Next Quarter Estimate | -0.10 | 1.37 | 61.00 |
Next Year Estimate | -0.43 | 7.08 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 55.21 | 17.20 | 15.67 |
Next Year | 0.00 | 16.10 | 9.31 |
Last 5 Years | NA | 0.10 | 8.10 |
Next 5 Years | NA | 14.00 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | 1.64 |
Price/Book (MRQ) | 13.86 | 1.38 |
Price/Cash Flow (MRFY) | NA | 10.63 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -833.60% | -55.42% |
Return on Equity (TTM) | -782.81% | -57.25% |
Debt to Equity (MRQ) | 0.75 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.